JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: As shown in Fig. 8, it presented a reasonable mechanism that Baicalein enhanced IM inhibition through suppressing JAK2/STAT5 pathway against CML CD34+ cells in vivo and in vitro.